Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Tacken PJ, de Vries IJ, Torensma R, Figdor CG
Nat Rev Immunol. 2007 Oct; 7(10):790-802.

The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs to create more effective vaccines. Early clinical trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell responses have provided proof of principle. Here, we discuss how direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo culturing, and facilitate large-scale application of DC-based vaccination therapies.

URL: http://www.nature.com/doifinder/10.1038/nri2173

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/17853902

created over 15 years ago (2 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]